Okay, let's tackle this question. The question is about which inhaled gas is used to decrease pulmonary artery pressure in adults and infants. First, I need to recall the drugs that act on pulmonary vascular resistance. The main ones I remember are nitric oxide and prostacyclin analogs.

Nitric oxide (NO) is a potent vasodilator. When inhaled, it directly acts on the pulmonary vasculature, causing smooth muscle relaxation and reducing pulmonary artery pressure. It's commonly used in conditions like pulmonary hypertension. But wait, there's also epoprostenol, which is a prostacyclin, but it's usually given intravenously, not inhaled. So that's probably not the answer here.

Another option might be volatile anesthetics like isoflurane, but they can cause systemic hypotension and might not be the first choice for pulmonary hypertension. Then there's sildenafil, which is an oral medication used for pulmonary hypertension, but the question specifically mentions an inhaled gas.

So the most likely correct answer is inhaled nitric oxide. Let me check the options again. The question lists options A to D, but the correct answer isn't specified. However, based on standard knowledge, inhaled NO is the standard treatment. The other options would be things like oxygen, which can help but isn't a pharmacological agent, or maybe something like helium, which is used for flow dynamics but not for lowering pulmonary pressure.

Wait, oxygen can decrease pulmonary artery pressure in hypoxic pulmonary vasoconstriction, but it's not an inhaled gas used specifically for that purpose in the same way as NO. So the correct answer should be nitric oxide. The other options are incorrect because they either don't target pulmonary vasculature directly or are administered differently. The clinical pearl here is that inhaled NO is the gold standard for acute management of pulmonary hypertension in both adults and infants.

**Core Concept**
The question tests knowledge of **pulmonary vasodilators**, specifically **inhaled nitric oxide (NO)**, which selectively reduces pulmonary vascular resistance by relaxing pulmonary artery smooth muscle without significant systemic hypotension. It is critical in managing **pulmonary hypertension** in neonates (e.g., persistent pulmonary hypertension of the newborn) and adults.

**Why the Correct Answer is Right**
**Inhaled nitric oxide (NO)** is a **vasodilator** that diffuses into pulmonary vascular smooth muscle, activating **guanylate cyclase** to increase **cyclic GMP (cGMP)**. This pathway promotes **smooth muscle relaxation** and **vasodilation**, selectively lowering pulmonary artery pressure. It is preferred over systemic vasodilators because it acts **locally** in the lungs, minimizing systemic hypotension. It is FDA-approved for both adults and infants.

**Why Each Wrong Option is Incorrect**
**Option A:** *Oxygen* reduces pulmonary pressure only in hypoxic pulmonary vasoconstriction but lacks direct vasodilatory action.
**Option B:** *Volatile anesthetics* (e.g., isoflurane) cause systemic and pulmonary vasodilation, risking hypotension; not first-line.
**Option C:** *Prostacyclin analogs* (e.g., epoprostenol) are **IV** agents, not inhaled.
**Option D:** *Phosph

✓ Correct Answer: C. Nitric oxide